Literature DB >> 29582720

Multidrug Resistant Acinetobacter baumanii: A 15-Year Trend Analysis.

Dana L Russell1, Daniel Z Uslan2, Zachary A Rubin2, Tristan R Grogan3, Elise M Martin2.   

Abstract

From 2000 to 2009, rates of multidrug-resistant Acinetobacter baumanii increased 10-fold to 0.2 per 1,000 patient days. From 2010 to 2015, however, rates markedly declined and have stayed below 0.05 per 1,000 patient days. Herein, we present a 15-year trend analysis and discuss interventions that may have led to the decline.Infect Control Hosp Epidemiol 2018;39:608-611.

Entities:  

Mesh：

Year:  2018        PMID： 29582720      PMCID： PMC7315822          DOI： 10.1017/ice.2018.52

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN： 0899-823X            Impact factor:   3.254


  8 in total

1.  Successful control of carbapenem-resistant Acinetobacter baumannii in a Korean university hospital: a 6-year perspective.

Authors:  Oh-Hyun Cho; Mi Hui Bak; Eun Hwa Baek; Ki-Ho Park; Sunjoo Kim; In-Gyu Bae
Journal:  Am J Infect Control       Date:  2014-09       Impact factor: 2.918

2.  Survival of Acinetobacter baumannii on dry surfaces.

Authors:  C Wendt; B Dietze; E Dietz; H Rüden
Journal:  J Clin Microbiol       Date:  1997-06       Impact factor: 5.948

3.  Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014.

Authors:  Lindsey M Weiner; Amy K Webb; Brandi Limbago; Margaret A Dudeck; Jean Patel; Alexander J Kallen; Jonathan R Edwards; Dawn M Sievert
Journal:  Infect Control Hosp Epidemiol       Date:  2016-08-30       Impact factor: 3.254

4.  Overview of nosocomial infections caused by gram-negative bacilli.

Authors:  Robert Gaynes; Jonathan R Edwards
Journal:  Clin Infect Dis       Date:  2005-08-16       Impact factor: 9.079

5.  Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010.

Authors:  Dawn M Sievert; Philip Ricks; Jonathan R Edwards; Amy Schneider; Jean Patel; Arjun Srinivasan; Alex Kallen; Brandi Limbago; Scott Fridkin
Journal:  Infect Control Hosp Epidemiol       Date:  2012-11-27       Impact factor: 3.254

6.  NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007.

Authors:  Alicia I Hidron; Jonathan R Edwards; Jean Patel; Teresa C Horan; Dawn M Sievert; Daniel A Pollock; Scott K Fridkin
Journal:  Infect Control Hosp Epidemiol       Date:  2008-11       Impact factor: 3.254

Review 7.  Current control and treatment of multidrug-resistant Acinetobacter baumannii infections.

Authors:  Drosos E Karageorgopoulos; Matthew E Falagas
Journal:  Lancet Infect Dis       Date:  2008-12       Impact factor: 25.071

8.  Controlling endemic multidrug-resistant Acinetobacter baumannii in Intensive Care Units using antimicrobial stewardship and infection control.

Authors:  Shinhye Cheon; Mi-Ja Kim; Seon-Jin Yun; Jae Young Moon; Yeon-Sook Kim
Journal:  Korean J Intern Med       Date:  2016-02-15       Impact factor: 2.884
  8 in total
  6 in total

1.  Trends in resistant Enterobacteriaceae and Acinetobacter species in hospitalized patients in the United States: 2013-2017.

Authors:  Vikas Gupta; Gang Ye; Melanie Olesky; Kenneth Lawrence; John Murray; Kalvin Yu
Journal:  BMC Infect Dis       Date:  2019-08-23       Impact factor: 3.090

2.  The epidemiology of carbapenem resistance in Acinetobacter baumannii complex in Germany (2014-2018): an analysis of data from the national Antimicrobial Resistance Surveillance system.

Authors:  Dunja Said; Niklas Willrich; Olaniyi Ayobami; Ines Noll; Tim Eckmanns; Robby Markwart
Journal:  Antimicrob Resist Infect Control       Date:  2021-03-01       Impact factor: 4.887

3.  Synergistic Inhibitory Effect of Polymyxin B in Combination with Ceftazidime against Robust Biofilm Formed by Acinetobacter baumannii with Genetic Deficiency in AbaI/AbaR Quorum Sensing.

Authors:  Yinyue Li; Bo Wang; Feng Lu; Juhee Ahn; Wenwen Zhang; Liangliang Cai; Jiahui Xu; Yi Yin; Qingchao Cao; Zhenyu Ren; Xinlong He
Journal:  Microbiol Spectr       Date:  2022-02-23

Review 4.  Pathogenesis of Gram-Negative Bacteremia.

Authors:  Caitlyn L Holmes; Mark T Anderson; Harry L T Mobley; Michael A Bachman
Journal:  Clin Microbiol Rev       Date:  2021-03-10       Impact factor: 26.132

5.  Comparison of the Clinical Characteristics of Hospital-Acquired and Non-Hospital-Acquired Acinetobacter calcoaceticus-baumannii Complex in a Large Midwest US Health Care System.

Authors:  Juan J Calix; Jason P Burnham; Mario F Feldman
Journal:  Open Forum Infect Dis       Date:  2019-10-04       Impact factor: 3.835

6.  Treatment outcomes of Acinetobacter baumannii -associated pneumonia and/or bacteraemia at the intensive care unit of Universitas Academic Hospital, Bloemfontein, South Africa.

Authors:  S D Maasdorp; S Potgieter; E Glover; G Joubert
Journal:  Afr J Thorac Crit Care Med       Date:  2021-03-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.